(Q37701553)

22 August 2017

1 reference

title

Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease (English)

1 reference

22 August 2017

1 reference

Juan José Badimón

1

1 reference

22 August 2017

Borja Ibáñez

series ordinal

2

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Revista Española de Cardiología

22 August 2017

published in

1 reference

22 August 2017

volume

63

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

323-333

1 reference

Classics in arteriosclerosis research: On experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Plaque progression and regression in atherothrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

The response-to-retention hypothesis of atherogenesis reinforced

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Arterial injury by cholesterol oxidation products causes endothelial dysfunction and arterial wall cholesterol accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Role of endothelial dysfunction in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Endothelial function. From vascular biology to clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Subendothelial retention of atherogenic lipoproteins in early atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Compensatory enlargement of human atherosclerotic coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Coronary Plaque Disruption

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Current perspective on the role of apoptosis in atherothrombotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Increasing HDL Cholesterol Levels

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

New insights into the regulation of HDL metabolism and reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Safe and sustained overexpression of functional apolipoprotein A-I/high-density lipoprotein in apolipoprotein A-I-null mice by muscular adeno-associated viral serotype 8 vector gene transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distri

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Rat Intestine Secretes Discoid High Density Lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Intestinal ABCA1 directly contributes to HDL biogenesis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Importance of different pathways of cellular cholesterol efflux

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

What is so special about apolipoprotein AI in reverse cholesterol transport?

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Lecithin cholesterol acyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Preferential Utilization of Free Cholesterol From High-Density Lipoproteins for Biliary Cholesterol Secretion in Man

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Endothelial and antithrombotic actions of HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Antiinflammatory properties of HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

High-density lipoproteins: epidemiologic profile and risks of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Prevalence of risk factors in men with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Safety and tolerability of dalcetrapib

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Apolipoprotein A-I and the molecular variant apoA-I(Milano): evaluation of the antiatherogenic effects in knock-in mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

[Novel imaging techniques for quantifying overall atherosclerotic burden]

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS1885-5857%2810%2970065-7

7 January 2021

10.1016/S1885-5857(10)70065-7

Identifiers

DOI

0 references

1 reference